Home > News > Headline News > Archive

Click on title to read the full article.

FDA votes to recommend removal of indication for bevacizumab in metastatic breast cancer

June 30, 2011

After 2 days of hearings, the FDA on Wednesday voted to strip the indication for bevacizumab for use in patients with metastatic breast cancer and said follow-up trials did not confirm positive PFS results observed in the E2100 trial.

Some Senior Breast Cancer Patients Don't Get Full Treatment

June 30, 2011

By Pam Stephan

Women over age 66 with metastatic breast cancer don't always get the full range of post-mastectomy treatments. A study done at MD Anderson Cancer Center in Houston showed that almost half of all senior women with advanced breast disease do not get radiation therapy after their surgery.

Alternative Pain Therapy for Breast, Prostate and Lung Cancer

June 29, 2011

Bio-Nucleonics’ lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

Iniparib Loses Blockbuster Image in Triple-Negative Breast Cancer

June 18, 2011

By Patrice Wendling

After having reported striking phase II data that sent both clinicians and patients with triple-negative breast cancer clamoring for iniparib, researchers are puzzling over a puny survival advantage in the phase III trial, and are questioning how the novel drug actually works.

ASCO: Drug Combo Fights Brain Mets

June 11, 2011

By Vandana G. Abramson, MD;

Systemic therapy with lapatinib (Tykerb) and capecitabine (Xeloda) may effectively treat brain metastases from HER2-positive breast cancer, delaying the need for brain irradiation, researchers found.

ASCO: Small Gains With Sorafenib in Metastatic Breast Ca

June 11, 2011

By Vandana G. Abramson, MD;

Pretreated advanced breast cancer slowed modestly but significantly with exposure to chemotherapy plus sorafenib (Nexavar), data from a randomized clinical trial showed.

ASCO: Platinum Chemo Equivalence Questioned

June 9, 2011

All platinum chemotherapy agents may not be as equally effective as often assumed, according to exploratory findings from a trial in metastatic triple-negative breast cancer.

ASCO: Study Calls PFS 'Weak' Endpoint in Breast Ca Mets

June 8, 2011

By Crystal Phend

Progression-free survival may not be a good surrogate endpoint in metastatic breast cancer, FDA researchers warned.

Bevacizumab improved pathological, clinical response rates in metastatic breast cancer

June 8, 2011

In results from NSABP protocol B-40 presented here today, Harry D. Bear, MD, PhD, said that the addition of bevacizumab to neoadjuvant chemotherapy improved both pathologic and clinical complete response in women with operable HER-2 negative breast cancer.

Algeta announces positive preliminary bone marker results in a phase IIa study evaluating Alpharadin in breast cancer patients w

June 8, 2011

A company focused on the development of novel targeted cancer therapeutics, today announced that preliminary data from its phase IIa study of Alpharadin (radium-223 chloride) for the treatment of bone metastases in 23 patients with endocrine-refractory breast cancer showed positive results for bone markers.

 1 2 >